Breaking News Instant updates and real-time market news.

SEEL

Seelos Therapeutics

$2.02

-0.1 (-4.72%)

09:02
07/17/19
07/17
09:02
07/17/19
09:02

Seelos Therapeutics announces IND application submission for SLS-005

Seelos Therapeutic announced that it has submitted an Investigational New Drug application with the U.S. Food and Drug Administration for the initiation of a Phase IIb/III clinical study of SLS-005 for the treatment of Sanfilippo syndrome. Seelos is working in collaboration and under a grant with Team Sanfilippo Foundation, a nonprofit foundation founded by parents of children with Sanfilippo syndrome. In May, Seelos announced the intention to expand this IND to be a combined Phase IIb/III, multicenter study designed to assess safety, tolerability and efficacy of trehalose IV in Sanfilippo A and B based on functional outcomes, biomarkers, neuro-cognitive assessments and quality of life measurements. Additionally, based on an overwhelming response from the Sanfilippo community worldwide, TSF, in collaboration with Seelos Therapeutics, has decided to expand inclusion of Sanfilippo type C and D patients as well as type A and B patients who do not meet the trial entry criteria into a separate expanded patient access study.

  • 20

    Aug

SEEL Seelos Therapeutics
$2.02

-0.1 (-4.72%)

05/10/19
HCWC
05/10/19
INITIATION
Target $4
HCWC
Buy
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright started Seelos Therapeutics with a Buy rating and $4 price target.
05/14/19
ROTH
05/14/19
INITIATION
Target $8
ROTH
Buy
Seelos Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started coverage of Seelos Therapeutics with a Buy rating and $8 price target. The analyst says the company has an "enriched" pipeline, with numerous milestones in 2019 and top-line results from PK/PD of SLS-002 to treat acute suicidality in early 2020.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.